Virchows Archiv,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 8, 2025
Abstract
Digital
Pathology
(DP)
revolutionizes
the
diagnostic
workflow.
Digitized
scanned
slides
enhance
operational
efficiency
by
facilitating
remote
access,
slide
storage,
reporting
and
automated
AI
image
analysis,
enabling
collaboration
research.
However,
substantial
upfront
maintenance
costs
remain
significant
barriers
to
adoption.
This
study
evaluates
DP’s
financial
qualitative
value,
exploring
whether
long-term
benefits
justify
investments
addressing
implementation
challenges
in
large
public
private
European
laboratory
settings.
A
targeted
literature
review,
semi-structured
interviews,
surveys,
a
net
present
value
(NPV)
model
were
employed
assess
impact
on
clinical
practice
financials.
Qualitative
findings
validate
key
of
DP,
including
optimized
workflow,
enhanced
logistics,
improved
organization.
Pathologists
reported
smooth
integration,
training,
teaching,
research
capabilities,
increased
flexibility
through
work.
Collaboration
within
multidisciplinary
teams
was
strengthened,
while
case
examination
access
archival
notably
improved.
Quantitative
results
indicate
that
DP
demonstrates
strong
potential,
achieving
cost
recovery
6
years.
investment
7-year
NPV
+
€0.21
million
(m)
driven
productivity
diagnosis
volumes.
Although
high
for
scanners,
system
integration
pose
barrier
adoption
larger
institutions
are
better
positioned
leverage
economies
scale.
underscores
importance
sustained
support
cope
with
initial
regional
driving
widespread
DP.
Expanding
reimbursement
policies
pathology
procedures
could
significantly
reduce
barriers.
Therapeutic Advances in Medical Oncology,
Journal Year:
2025,
Volume and Issue:
17
Published: Jan. 1, 2025
Despite
the
availability
of
multiple
treatment
options
for
breast
cancer,
challenges
such
as
adverse
events,
drug
resistance,
and
disease
progression
persist
patients.
The
identification
human
epidermal
growth
factor
receptor
2
(HER2)
an
oncogenic
driver
in
a
subset
cancers,
alongside
development
HER2-targeted
therapies,
has
significantly
improved
prognosis
HER2-amplified
cancers.
However,
therapeutic
remain
limited
HER2-overexpressing
or
HER2-negative
In
response
to
this
gap,
antibody-drug
conjugates
(ADCs)
have
emerged
promising
approach.
ADCs
combine
specificity
monoclonal
antibodies
with
cytotoxic
effects
chemotherapy,
which
allows
targeted
delivery
payload
cancer
cells.
been
used
adjuvant
chemotherapeutic
treatments
salvage
therapies
across
various
subtypes,
greatly
Numerous
ongoing
clinical
trials
seek
optimize
dosing
strategies
identify
patient
populations
that
would
benefit
most
from
ADCs.
This
review
presents
updated
comprehensive
overview
emerging
investigational
treating
patients
HER2
subtypes.
These
are
spearheading
new
era
therapy,
innovate
paradigms
both
HER2-positive
HER2-low
Journal of Clinical Oncology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 27, 2025
Living
guidelines
are
developed
for
selected
topic
areas
with
rapidly
evolving
evidence
that
drives
frequent
change
in
recommended
clinical
practice.
updated
on
a
regular
schedule
by
standing
expert
panel
systematically
reviews
the
health
literature
continuous
basis,
as
described
ASCO
Guidelines
Methodology
Manual
.
follow
Conflict
of
Interest
Policy
Implementation
Clinical
Practice
and
updates
not
intended
to
substitute
independent
professional
judgment
treating
clinician
do
account
individual
variation
among
patients.
See
appendix
disclaimers
other
important
information
(
Appendix
1
2
).
Updates
published
regularly
can
be
found
at
https://ascopubs.org/nsclc-non-da-living-guideline
Virchows Archiv,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 8, 2025
Abstract
Digital
Pathology
(DP)
revolutionizes
the
diagnostic
workflow.
Digitized
scanned
slides
enhance
operational
efficiency
by
facilitating
remote
access,
slide
storage,
reporting
and
automated
AI
image
analysis,
enabling
collaboration
research.
However,
substantial
upfront
maintenance
costs
remain
significant
barriers
to
adoption.
This
study
evaluates
DP’s
financial
qualitative
value,
exploring
whether
long-term
benefits
justify
investments
addressing
implementation
challenges
in
large
public
private
European
laboratory
settings.
A
targeted
literature
review,
semi-structured
interviews,
surveys,
a
net
present
value
(NPV)
model
were
employed
assess
impact
on
clinical
practice
financials.
Qualitative
findings
validate
key
of
DP,
including
optimized
workflow,
enhanced
logistics,
improved
organization.
Pathologists
reported
smooth
integration,
training,
teaching,
research
capabilities,
increased
flexibility
through
work.
Collaboration
within
multidisciplinary
teams
was
strengthened,
while
case
examination
access
archival
notably
improved.
Quantitative
results
indicate
that
DP
demonstrates
strong
potential,
achieving
cost
recovery
6
years.
investment
7-year
NPV
+
€0.21
million
(m)
driven
productivity
diagnosis
volumes.
Although
high
for
scanners,
system
integration
pose
barrier
adoption
larger
institutions
are
better
positioned
leverage
economies
scale.
underscores
importance
sustained
support
cope
with
initial
regional
driving
widespread
DP.
Expanding
reimbursement
policies
pathology
procedures
could
significantly
reduce
barriers.
